Intravenous Transplantation of Bone Marrow-Derived Mesenchymal Stem Cells Combined with Subcutaneous Recombinant Human Growth Hormone Improves Cardiac Function in Rats with Adriamycin-Induced Cardiomyopathy and Heart Failure

Li Wang
2007-01-01
Abstract:Objective To study the effects of bone marrow mesenchymal stem cells (MSCs) intravenous transplantation in combination with recombinant human growth hormone (rGH) on cardiac function of rats with adriamycin-induced cardiomyopathy and heart failure. Methods (1) MSCs cells were isolated, cultured in vitro, and then purified. The cultured cells were detected for surface markers including CD45, CD44 and CD71, using a flow cytometer. (2) Of 50 Wistar rats, models of adriamycin-induced cardiomyopathy and heart failure were successfully generated in 40. These rats were randomized into one of 4 groups to receive MSCs intravenous transplantation via the caudal vein (MSC group), subcutaneous rGH (rGH group), combined use of IV MSC and rGH (MSC + rGH group), or nothing (heart failure group). At 4 weeks, cardiac function was evaluated by echocardiography and hemodynamic measurement. Results Flow cytometric analysis showed that the second-passage MSC expressed CD44 and CD71 but not CD34. The cardiac function was improved in all treatment groups in terms of echocardiography and hemodynamic findings. Compared with heart failure group, MSC+rGH group showed greater improvement in cardiac function than MSC group and rGH group. Conclusion MSC intravenous transplantation in combination with rGH provides significant benefits in rats with adriamycin-induced cardiomyopathy and heart failure.
What problem does this paper attempt to address?